scholarly journals Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

2002 ◽  
Vol 86 (5) ◽  
pp. 356-364 ◽  
Author(s):  
E Astrom
Keyword(s):  
Osteogenesis Imperfecta ◽  
Beneficial Effect ◽  
Bisphosphonate Treatment ◽  
Intravenous Bisphosphonate

Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen

2014 ◽  
Vol 81 (3) ◽  
pp. 204-210 ◽  
Author(s):  
Andrew Biggin ◽  
Julie N. Briody ◽  
Elizabeth Ormshaw ◽  
Karen K.Y. Wong ◽  
Bruce H. Bennetts ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Treatment Regimen ◽  
Low Dose ◽  
Bisphosphonate Treatment ◽  
Dose Treatment ◽  
Intravenous Bisphosphonate

Near-Infrared Imaging Reveals Site- and Age-Specific Localization of Bisphosphonate Delivery and Retention in Model of Osteogenesis Imperfecta

2009 ◽  
Author(s):  
Kenneth M. Kozloff ◽  
Leo I. Volakis ◽  
Joan C. Marini ◽  
Michelle S. Caird
Keyword(s):  
Osteogenesis Imperfecta ◽  
Near Infrared ◽  
Bending Strength ◽  
Infrared Imaging ◽  
Term Treatment ◽  
Bisphosphonate Treatment ◽  
Long Term Treatment ◽  
Prevention Of Osteoporosis

Bisphosphonate use has expanded beyond traditional applications, such as the prevention of osteoporosis, into non-traditional pediatric low bone mass diseases including osteogenesis imperfecta (OI) [1]. Despite enthusiasm, some questions remain on the overall effectiveness and implications of long-term treatment. In the Brtl/+ mouse model for OI, bisphosphonate treatment improves bone size, but bending strength fails to increase to proportionate levels and bones remain brittle [2]. Complications associated with long-term bisphosphonate treatment have been noted in other systems [3,4] leading to a need for critical information describing local drug-cell interactions responsible for these observations. The purpose of this study was to validate a fluorescent bisphosphonate analog, far-red fluorescent pamidronate (FRFP) [5] as a biomarker of bisphosphonate deposition and retention in vivo to monitor local drug concentration in a site-specific manner.

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy

2020 ◽  
Vol 30 (7) ◽  
pp. 599-610
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Irina Rybalsky ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Glucocorticoid Therapy ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate

scholarly journals Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment

2021 ◽  
Vol 43 (1) ◽  
Author(s):  
Seung-Hun Lee ◽  
So-Young Choi ◽  
Min-Su Bae ◽  
Tae-Geon Kwon
Keyword(s):  
Retrospective Study ◽  
Clinical Characteristics ◽  
Demographic Data ◽  
Osteonecrosis Of The Jaw ◽  
Group Differences ◽  
Bisphosphonate Treatment ◽  
Administration Route ◽  
Lesion Number ◽  
Different Characteristics ◽  
Intravenous Bisphosphonate

Abstract Purpose This retrospective study was aimed to evaluate the clinical characteristics and treatment outcomes in patients with osteonecrosis of the jaw who were receiving oral versus intravenous (IV) bisphosphonate (BP). Materials and methods This retrospective study enrolled subjects who had been diagnosed with medication-related osteonecrosis of the jaw (MRONJ) during the period from July 2010 to June 2014. Information regarding the following demographic and clinical characteristics was collected: demographic data, administration route and type of BP, duration of BP medication, primary disease, number of involved sites, location of the lesion, number of surgeries, outcome of treatments, and laboratory test. All the patients were divided into oral and IV BP groups; and the between-group differences were compared. Results Total 278 patients were divided into two groups as per the route of BP administration. The proportion of oral BP-related MRONJ group were more dominant over IV BP group (oral BP, n = 251; IV BP, n = 27). In the IV BP group, the average dosing duration (31.4 months) was significantly shorter than that in the oral BP group (53.1 months) (P < 0.001). The average number of involved sites in the oral BP group (1.21 ± 0.48) was smaller than that in the IV BP group (1.63 ± 0.84) (P < 0.001). The average number of surgeries was higher in the IV BP group (1.65 ± 0.95) as compared to that in the oral BP group (0.98 ± 0.73) (P < 0.001). Outcome after the surgery for MRONJ after IV BP was poor than oral BP group. Conclusion IV administration of BP causes greater inhibition of bone remodeling and could lead more severe inflammation. Therefore, even if the duration of IV administration of BP is shorter than that of oral BP, the extent of the lesion could be more extensive. Therefore, the result suggests that the MRONJ after IV BP for cancer patients needs to be considered as different characteristics to oral BP group for osteoporosis patents.

EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA

2016 ◽  
Vol 22 (12) ◽  
pp. 1369-1376 ◽  
Author(s):  
Fang Lv ◽  
Yi Liu ◽  
Xiaojie Xu ◽  
Jianyi Wang ◽  
Doudou Ma ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Pediatric Patients ◽  
Large Sample ◽  
Alendronate Treatment

Intravenous Bisphosphonate Therapy in Children With Osteogenesis Imperfecta

PEDIATRICS ◽  
2003 ◽  
Vol 111 (3) ◽  
pp. 573-578 ◽  
Author(s):  
M. J. Falk ◽  
S. Heeger ◽  
K. A. Lynch ◽  
K. R. DeCaro ◽  
D. Bohach ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Bisphosphonate Therapy ◽  
Intravenous Bisphosphonate

Beneficial effect of statins on total mortality in abdominal aortic aneurysm (AAA) repair

2017 ◽  
Vol 22 (5) ◽  
pp. 406-410 ◽  
Author(s):  
Sven Ross Mathisen ◽  
Michael Abdelnoor
Keyword(s):  
Cohort Study ◽  
Beneficial Effect ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Open Surgery ◽  
Total Mortality ◽  
Abdominal Aortic ◽  
Statin Use

In this single center, retrospective cohort study we wished to compare early and total mortality for all patients treated for abdominal aortic aneurysms (AAA) with open surgery who were taking statins compared to those who were not. A cohort of 640 patients with AAA was treated with open surgery between 1999 and 2012. Patients were consecutively recruited from a source population of 390,000; 21.3% were female, and the median age was 73 years. The median follow-up was 3.93 years, with an interquartile range of 1.79–6.58 years. The total follow-up was 2855 patient-years. An explanatory strategy was used. The propensity score (PS) was implemented to control for selection bias and confounders. The crude effect of statin use showed a 78% reduction of the 30-day mortality. A stratified analysis using the Mantel–Haenszel method on quintiles of the PS gave an adjusted effect of the odds ratio equal to 0.43 (95% CI: 0.18–0.96), indicating a 57% reduction of the 30-day mortality for statin users. The adjusted rate ratio was 0.62 (95% CI: 0.45–0.83), indicating a reduction of long-term mortality of 38% for statin users compared to non-users for a median follow-up of 3.93 years. This retrospective cohort study showed a significant beneficial effect of statin use on early and long-term survival for patients treated with open surgery. To be conclusive, our results need to be replicated by a randomized clinical trial.

The Cost-Effectiveness of an RCT to Establish Whether 5 or 10 Years of Bisphosphonate Treatment Is the Better Duration for Women With a Prior Fracture

2009 ◽  
Vol 29 (6) ◽  
pp. 678-689 ◽  
Author(s):  
Matt D. Stevenson ◽  
Jeremy E. Oakley ◽  
Myfawny Lloyd Jones ◽  
Alan Brennan ◽  
Juliet E. Compston ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Effective ◽  
Fracture Prevention ◽  
Published Data ◽  
Bisphosphonate Treatment ◽  
Net Benefit ◽  
England And Wales ◽  
Term Efficacy ◽  
The Cost

Purpose. Five years of bisphosphonate treatment have proven efficacy in reducing fractures. Concerns exist that long-term bisphosphonate treatment may actually result in an increased number of fractures. This study evaluates, in the context of England and Wales, whether it is cost-effective to conduct a randomized controlled trial (RCT) and what sample size may be optimal to estimate the efficacy of bisphosphonates in fracture prevention beyond 5 years. Method. An osteoporosis model was constructed to evaluate the cost-effectiveness of extending bisphosphonate treatment from 5 years to 10 years. Two scenarios were run. The 1st uses long-term efficacy data from published literature, and the 2nd uses distributions elicited from clinical experts. Results of a proposed RCT were simulated. The expected value of sample information technique was applied to calculate the expected net benefit of sampling from conducting such an RCT at varying levels of participants per arm and to compare this with proposed trial costs. Results. Without further information, the better duration of bisphosphonate treatment was estimated to be 5 years using the published data but 10 years using the elicited expert opinions, although in both cases uncertainty was substantial. The net benefit of sampling was consistently high when between 2000 and 5000 participants per arm were recruited. Conclusions. An RCT to evaluate the long-term efficacy of bisphosphonates in fracture prevention appears to be cost-effective for informing decision making in England and Wales.

Sign in / Sign up

Export Citation Format

Share Document